Introduction {#Sec1}
============

Breast cancer has the highest incidence among all cancers and is the second most common cause of mortality in women around the world \[[@CR1]\]. Endocrine therapy, cytotoxic chemotherapy, and targeted therapy are widely used as medical therapeutic strategies for breast cancer patients \[[@CR2], [@CR3]\]. Despite the increasing 5-year survival rate in recent years, drug resistance is still a major cause of death due to breast cancer and an important issue that remains to be addressed in cancer chemotherapy \[[@CR4], [@CR5]\].

Dexamethasone (DEX) is a commonly used synthetic glucocorticoid in clinical practice. Several studies have reported the antitumor potency of DEX in breast cancer, lung cancer, pancreatic cancer \[[@CR6]--[@CR9]\], etc. In our previous study, DEX was found to be efficacious in breast cancer either individually or in combination with other chemotherapy drugs, such as gemcitabine \[[@CR7], [@CR10]\]. DEX downregulate the estrogen level by the glucocorticoid receptor-mediated induction of estrogen sulfotransferase, which has been demonstrated in both breast cancer and non-small cell lung cancer (NSCLC) \[[@CR6], [@CR8]\], and further results in the inhibition of tumor growth. Moreover, DEX works on preventing the activation of nuclear factor-kappa B (NF-κB) \[[@CR11]\] and inhibiting VEGF by downregulating the expression of HIF-1α \[[@CR12]\], all of which contribute to its antitumor efficacy.

Cancer stem-like cells (CSCs) are thought to be involved in tumor drug resistance, recurrence, metastasis, and poor prognosis \[[@CR13], [@CR14]\]. Dopamine receptors (DRs) were found to be a potential target in CSCs, where the activation of dopamine D~1~-like receptor (D1DR) \[[@CR15]\] and antagonism of dopamine D~2~-like receptor (D2DR) \[[@CR16], [@CR17]\] were both reported to be effective at suppressing CSCs and cancer therapy. Sulpiride (SUL) works as a specific D2DR antagonist in the treatment of schizophrenia \[[@CR18]\] and is therefore considered helpful in inhibiting CSCs. We applied the combination of DEX and SUL to drug-resistant breast cancer xenografts, and the results showed that SUL prominently promoted the effect of DEX on inhibiting the growth of drug-resistant breast cancer by antagonizing D2DR, indicating the involvement of a CSC-related mechanism \[[@CR19]\].

As shown in a previous study \[[@CR10]\], the self-induction of CYP3A by DEX resulted in time-dependent pharmacokinetic (PK) changes in DEX over multiple doses. In addition, the double-peak absorption PKs of SUL after oral administration was found in humans; however, there have been no studies on the PKs of SUL in nude mice. Additionally, a synergistic pharmacodynamic (PD) interaction between DEX and SUL has been observed \[[@CR19]\], which requires quantitative analysis and further investigation. Based on the experimental results, the aim of this study is to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the combinatorial use of DEX and SUL to quantitatively describe their antitumor efficacy and provide some insight into their synergistic interaction. Moreover, the simulation model may be helpful to optimize the dose regimen to achieve better efficacy.

Materials and methods {#Sec2}
=====================

Chemicals and reagents {#Sec3}
----------------------

DEX and SUL were purchased from Sigma--Aldrich (MO, USA). RPMI-1640 medium was purchased from Macgene Biotech Co., Ltd. (Beijing, China), and fetal bovine serum (FBS) was supplied by Gibco (New York, USA). Other chemicals were obtained from Beijing Chemical Works (Beijing, China).

Cell culture {#Sec4}
------------

The human breast cancer cell line MCF-7/Adr was supplied by the Institute of Materia Medica, Chinese Academy of Medical Sciences (Beijing, China) as a drug-resistant breast cancer cell line. The cells were cultured in RPMI-1640 medium with 10% FBS at 37 °C in a 5% CO~2~-containing atmosphere.

Animals {#Sec5}
-------

Female nude mice (20 ± 2 g, 4--5 weeks of age) were purchased from Vital River (Beijing, China). The mice were housed in individual ventilated cages under standard pathogen-free conditions (50%--60% humidity, 22--24 °C, and 12 h/12 h light/dark cycle). The animals were given free access to food and water, except the mice used for PK study, which were fasted for 12 h before administration. All animal studies were approved by the Institutional Animal Care and Use Committee of Peking University Health Science Center.

PD study {#Sec6}
--------

The PD study was conducted according to our previous study \[[@CR19]\]. Briefly, MCF-7/Adr cells were subcutaneously injected into nude mice to establish an orthotopic breast cancer xenograft model. Tumor-bearing mice were divided into 11 groups (*n* = 5) and subjected to treatment 5 days after implantation. Mice in the control group were administered vehicle solutions daily. In the five monotherapy groups, mice were given SUL (25 or 100 mg/kg, *p.o.*) or DEX (1, 2, or 8 mg/kg, *p.o.*) every day. For the combination groups, mice simultaneously received DEX (1 mg/kg) with SUL (50 mg/kg) or DEX (8 mg/kg) with SUL (25, 50 mg/kg). Tumor volumes were recorded every other day and calculated as follows: tumor volume (mm^3^) = length × width^2^ × 0.5.

PK model and simulation {#Sec7}
-----------------------

The time-dependent PK model for DEX has been described in another study \[[@CR10]\]. The PK properties of DEX were characterized by a two-compartment model with first-order absorption rate and time-dependent clearance, reflecting the self-induction of CYP3A by DEX when persistently administered \[[@CR20]\]. The PK parameter estimates and the details of the model are given in our publication \[[@CR10]\].

An LC-MS/MS method for determining the plasma concentration of SUL in nude mice was developed and further validated. Briefly, chromatographic separation was performed on a UHPLC system (Dionex UltiMate 3000) and an API4000 QTRAP mass spectrometer (Applied Biosystems Inc., USA) was equipped with an electrospray ionization (ESI) source system. A reverse-phase Phenomenex Luna C18(2) column (250 × 4.60 mm, 5 μm) was employed. Analytes were eluted with a gradient mobile phase composed of acetonitrile and water containing 5 mM ammonium formate (Supplementary Table [S1](#MOESM1){ref-type="media"}). A 5 μL working solution was added to 95 μL blank plasma for calibration of standards, and quality control (QC) samples were treated with 2 mL of ethyl acetate and centrifuged. Then, 1.8 mL of the organic layer was collected and dried under nitrogen. Then, the residue was reconstituted in 120 µL of methanol, and a 5 µL aliquot was injected for analysis. Erlotinib was selected as an internal standard. Method validation was performed according to the US Food and Drug Administration (FDA, USA) guidelines for bioanalytical method validation (US Food and Drug Administration, 2018), including the intra- and inter-day precision and accuracy, recovery, matrix effect, and stability.

In the PK study, SUL was dissolved in 45% (*w*/*v*) hydroxypropyl-β-cyclodextrin aqueous solution and given orally at 50 mg/kg as a single dose. Blood samples were collected by extracting eyeballs at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 h after administration, and three nude mice were sacrificed at each time point. The blood samples were collected into heparinized tubes and centrifuged at 1180 × *g* for 10 min, and the supernatant was kept at −20 °C. Approximately 100 μL plasma samples were identically prepared from the calibration standards and QC samples.

The PK profiles of SUL were described by a two-compartment model with a double first-order absorption rate at two sites, accounting for the efflux caused by P-glycoprotein (P-gp) and reabsorption in the intestine \[[@CR21]\]. The differential equations are as follows:$$\documentclass[12pt]{minimal}
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Simulations for multiple administration were performed based on parameter estimates. The PK profiles of SUL after multiple doses at 25 mg/kg and 50 mg/kg were simulated.

The structures of both PK models were integrated into the final PK/PD model (Fig. [1](#Fig1){ref-type="fig"}). All parameter estimates were fixed to fit the final PK/PD model.Fig. 1A schematic representation of the PK/PD model for the combinatorial use of DEX and SUL

PK/PD model construction, evaluation, and simulation {#Sec8}
----------------------------------------------------

The tumor natural growth model in this study was characterized by Koch et al. \[[@CR22]\], in which tumor growth was described by an exponential growth rate followed by a linear growth rate without a threshold between the two phases. The differential equation is as follows:$$\documentclass[12pt]{minimal}
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The PK/PD model was subsequently developed by adding drug effects on tumor natural growth. DEX exhibited its antitumor efficacy by inhibiting the proliferation of tumor cells \[[@CR10]\] in the form of Hill's function instead of stimulating their eradication \[[@CR7]\], based on its effect on decreasing estrogen and other factors involved in tumor progression, such as NF-κB and HIF-1α \[[@CR6], [@CR8], [@CR11], [@CR12]\]. The differential equation is as follows \[[@CR10]\]:$$\documentclass[12pt]{minimal}
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In the final PK/PD model, we assumed that SUL exerted its effect by sensitizing tumor cells to the antitumor effect of DEX with a Hill's function, as shown in Eq. [9](#Equ9){ref-type=""}. Another assumption is that there is no PK interaction between DEX and SUL. The structure of the combination model is shown in Fig. [1](#Fig1){ref-type="fig"}.$$\documentclass[12pt]{minimal}
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Modeling and simulation in this study were conducted using NONMEM 7.2.0 (ICON Development Solutions, Ellicott City, MD, USA) and PsN 4.2.0 (Uppsala University, Uppsala, Sweden) with first-order conditional estimation with interaction (FOCEI) method. The interindividual variability (IIV) and the residual variability were assumed to follow a log-normal distribution. Exponential models were employed to characterize IIV, and a mixed error model was selected for the residual error model. Relative standard errors (RSE) were shown to evaluate the precision and reliability of the estimates. Models were evaluated and selected depending on the rationality of the estimates, change in objective function value (OFV), diagnostic plots, and visual predictive check (VPC) with 1000 simulations.

Simulations for different dosing regimens were performed based on parameter estimates of the final PK/PD model. The dosing frequencies for both DEX and SUL were changed while the total doses remained constant. In addition, the dosing schedule of DEX at 8 mg/kg given every day and SUL at 50 mg/kg administered 6 h later was simulated, and five nude mice were used to execute the same schedule (DEX given at 9:00 AM, SUL given at 3:00 PM, qd). The observed data were then compared with the model predictions for external validation.

Statistical analysis {#Sec9}
--------------------

The results for the PK and PD study are shown as the mean ± SD, and statistical analyses were performed with GraphPad Prism 5.0 software (La Jolla, USA).

Results {#Sec10}
=======

Pharmacokinetic model for SUL {#Sec11}
-----------------------------

A highly sensitive LC-MS/MS method for the quantitation of SUL in nude mouse plasma was developed and further validated. The typical multiple reaction monitoring mode chromatograms of blank nude mouse plasma, plasma samples spiked with SUL and IS, and plasma samples collected 0.5 h after the administration of SUL demonstrated the specificity of the method (Supplementary Fig. [S1](#MOESM1){ref-type="media"}). The calibration curves were linear within the range of 0.4--1000 ng/mL (*y* = 0.00626*x* + 0.000867, *r* \> 0.99) with the lower limit of quantitation (LLOQ) of 0.4 ng/mL, and a 1/*x* weighting factor was chosen to achieve the linear regression. The precision and accuracy (Supplementary Table [S2](#MOESM1){ref-type="media"}), recovery and matrix effect (Supplementary Table [S3](#MOESM1){ref-type="media"}), and the stability (Supplementary Table [S4](#MOESM1){ref-type="media"}) of the method were validated, and they were in accordance with the requirements of the FDA.

According to the PK profiles of SUL after a single dose at 50 mg/kg, the first peak plasma concentration was observed approximately 1 h after administration, while the second peak was observed at \~2 h, suggesting that double absorption rates should be taken into consideration. The two-compartment model with a double first-order absorption rate fit the data well, and VPC was performed (Fig. [2a, b](#Fig2){ref-type="fig"}, Supplementary Fig. [S2](#MOESM1){ref-type="media"}). The estimate of *K*~a2,sul~ was 538 h^−1^, much higher than 1.66 h^−1^ of *K*~a1,sul~, and the *T*~lag~ between the two absorption phases was 1.5 h (Table [1](#Tab1){ref-type="table"}), which reasonably described the double peaks in plasma concentration. The *V*~c,sul~/*F* estimate (59.6 L/kg) was much lower than *V*~p,sul~*/F* (392 L/kg), which was in agreement with the results of the PK properties of SUL in humans \[[@CR23]\]. The simulated PK profiles of SUL after multiple doses at 25 mg/kg and 50 mg/kg suggested that a steady state of SUL plasma concentration was achieved on the sixth day after the first dose when SUL was administered every day (Fig. [2c](#Fig2){ref-type="fig"}).Fig. 2**a** The fitness of the PK model for SUL after a single oral dose of 50 mg/kg. **b** VPC results of the established PK model. The dots indicate observed data, the solid red line is the fiftieth percentile of observed data, the shaded blue area represents the 95% CI for the fifth and ninety-fifth percentiles of the predicted data, and the shaded red area represents the 95% CI for the fiftieth percentile of the predicted data. **c** The simulated PK profiles of SUL under different dose regimens. SUL was administered at 25 or 50 mg·kg^−1^·d^−1^Table 1Parameter estimates of the PK model for SULParametersDefinitionEstimates (%RSE)IIV (%CV)*K*~a1,sul~ (h^−1^)First-order absorption rate of SUL at the first site1.66 (5.3)0 FIX*K*~a2,sul~ (h^−1^)First-order absorption rate of SUL at the second site538 (2.1)0 FIXfFraction of SUL absorbed at the first absorption site0.818 (17.1)0 FIX*V*~c,sul~/F (L/kg)Apparent volumes of distribution in the central compartment of SUL59.6 (24.2)0 FIX*V*~p,sul~/F (L/kg)Apparent volumes of distribution in the peripheral compartment of SUL392 (34.9)136.4CL~sul~/F (L·kg^−1^·h^−1^)Systematic clearance of SUL12.1 (1.5)0 FIXQ~sul~/F (L·kg^−1^·h^−1^)Clearance between central and peripheral compartments of SUL29.4 (3.6)0 FIX*T*~lag~ (h)Time lag between the two absorption sites1.500 FIXσ ~prop,sul~ (%)Proportional residual error19.7%

PK/PD model for the combination of DEX with SUL {#Sec12}
-----------------------------------------------

In the final PK/PD model, the estimate of IC~50~ was 61.6 ng/mL within a reasonable range of SUL plasma concentrations, and the RSE of the estimates were acceptable (Table [2](#Tab2){ref-type="table"}). In the goodness-of-fit (GOF) plots (Supplementary Fig. [S3](#MOESM1){ref-type="media"}), the population predictions and individual predictions versus observation plots followed a symmetric distribution around the diagonal line, and the conditional weighted residuals were randomly distributed within the range of −4 and 4. The individual fitting plots (Fig. [3](#Fig3){ref-type="fig"}) suggested that the individual predictions were basically in accordance with the observed data. The diagnosis plots demonstrated that the PK/PD model fit the model well.Table 2Parameter estimates of the PK/PD model for the combination of DEX and SULParametersDefinitionEstimates (%RSE)IIV (%CV)λ~0~ (h^−1^)^a^Exponential tumor growth rate0.0065 (8.9)0 FIXλ~1~ (mm^3^·h^−1^)^a^Linear tumor growth rate28.1 (28.7)21.1ω~0~ (mm^3^)^a^Initial tumor volume38 (20.4)23.5EC~50~ (ng/mL)^a^DEX concentration when half of the maximal antitumor effect was achieved61.6 (18.8)72.6IC~50~ (ng/mL)SUL concentration when half of the maximal sensibilization effect on DEX was achieved61.9 (36.8)138.2σ~prop~ (%)Proportional residual error in PK/PD model30%σ~add~ (mm^3^)Additive residual error in PK/PD model20.8^a^parameter estimates were from publication \[[@CR9]\]Fig. 3Individual fits of the PK/PD model for DEX combined with SUL. ID = 1--5, DEX 1 mg·kg^−1^·d^−1^ combined with SUL 50 mg·kg^−1^·d^−1^; ID = 6--10, DEX 8 mg·kg^−1^·d^−1^ combined with SUL 25 mg·kg^−1^·d^−1^; ID = 11--15, DEX 8 mg·kg^−1^·d^−1^ combined with SUL 50 mg·kg^−1^·d^−1^. DV observed data, IPRED individual predicted tumor size, PRED predicted tumor size

The VPC results based on 1000 simulations are shown in Fig. [4](#Fig4){ref-type="fig"}. Most of the observations fell within the 90% confidence interval of predictions, indicating that the model had good ability to predict tumor natural growth and the antitumor effect of DEX combined with SUL.Fig. 4The VPC results of the integrated PK/PD model for DEX combined with SUL based on 1000 simulations. The dots are the observed data, and the solid red line represents the 50th percentile of observed data; the blue shaded area represents the 95% CI for the fifth and ninty-fifth percentiles of the predicted data; and the shaded red area represents the 95% CIs for the fiftieth percentile of the predicted data

Model simulations {#Sec13}
-----------------

Simulations for different dosing regimens were performed by fixing the PK/PD parameters. The changes in dosing frequency when the total dose of SUL was kept constant made no difference in the predicted tumor volumes (Fig. [5a](#Fig5){ref-type="fig"}), while the antitumor efficacy of the combination was predicted to be better when DEX was administered more frequently (Fig. [5b, c](#Fig5){ref-type="fig"}). The results suggested that increasing the dosing frequency of DEX when possible might improve its antitumor efficacy.Fig. 5Simulated tumor growth kinetics under different dose regimens. The dose schedules are presented in related legends (**a**, **b**, and **c**). External validation of the PK/PD model with the dosing schedule of 8 mg·kg^−1^·d^−1^ DEX and 50 mg·kg^-1^·d^-1^ SUL given in 6-h intervals. The solid line represents the simulated tumor size, and the dots represent the observed tumor sizes (**d**)

In addition, the dosing schedule of DEX at 8 mg·kg^−1^·d^−1^ combined with SUL at 50 mg·kg^−1^·d^−1^ administered 6 h after DEX was predicted and implemented in the experiment. The experimental data were in good agreement with the predictions, further confirming the predictability of the model by external validation (Fig. [5d](#Fig5){ref-type="fig"}).

Discussion {#Sec14}
==========

The antitumor efficacy of DEX has been reported in several publications \[[@CR6], [@CR9]\] and was further confirmed by our previous studies \[[@CR7], [@CR8]\]. On the other hand, D2DR antagonists have been utilized in combination with chemotherapy drugs in lung cancer \[[@CR17]\]. Since both DEX and SUL are commonly used clinical drugs without major safety issues, especially in cancer \[[@CR18], [@CR24]\], along with their low cost to patients, we investigated the antitumor efficacy of the combination in a preclinical drug-resistant breast cancer xenograft model and the underlying mechanism \[[@CR19]\]. In this study, we mainly focused on the PK/PD model for combination therapy with DEX and SUL and its application using simulations. The PK model for SUL with the assumption of two absorption peaks was established. Thus, the effects of transporters and drug metabolizing enzymes were simultaneously considered in the combination PK/PD model. Meanwhile, the PD effect of SUL for reducing the apparent EC~50~ in the combination PK/PD model is completely new compared with our previous published model. Moreover, the developed PK/PD model quantitatively described the synergism between DEX and SUL and was further applied to simulations for different dosages, which could be conductive to future studies.

In the PK model for SUL, various structures were tried to capture the double peaks of plasma concentration: zero-order absorption rate alone, first-order absorption rate alone, zero-order absorption rate together with first-order absorption rate, zero-order absorption rate followed by first-order absorption rate, and double first-order absorption rate at two sites. In addition, both one-compartment and two-compartment models were used for the structure. Finally, a two-compartment model with a double first-order absorption rate was selected. It has been reported that SUL is the substrate of P-gp when absorbed in the gastrointestinal (GI) tract, and some SUL is pumped out by P-gp and then reabsorbed in the GI \[[@CR21]\] tract, accounting for the two peaks in the plasma concentration curve. Hence, the double absorption rate suggested that dual absorption occurred at different sites, capturing the process of absorption and reabsorption in the GI tract, where *T*~*lag*~ was used to describe the time lag between the dual absorption pattern, consistent with the PK model for SUL in humans \[[@CR23]\].

In the PK/PD model for DEX combined with SUL, the effect of SUL was characterized by the enhancement of sensitivity to DEX. SUL showed no significant effect on tumor growth when administered alone, but the antitumor efficacy of DEX was significantly improved when combined with SUL compared to that of monotherapy with DEX at the same dose \[[@CR10]\]. Our previous work has demonstrated that SUL significantly downregulates the CSC frequency in drug-resistant breast cancer by antagonizing D2DR, although CSCs account for only 11.27% of cells in the preclinical drug-resistant breast cancer xenograft, in addition to having a limited impact on differentiated tumor cells \[[@CR19]\]. However, DEX exerts its antitumor effect by inhibiting the natural growth of tumor cells and is taken up by the majority of tumor cells except for CSCs \[[@CR6], [@CR10]\]. Thus, the combination of DEX and SUL shows a good synergistic effect, and the parameter IC~50~ indicates the additive effect of SUL on the EC~50~, indicating the sensitivity of tumor natural growth to DEX. The effects of both DEX and SUL were characterized by Hill's function with the *E*~*max*~ (or *I*~*max*~) fixed to 1, because the model failed to perform well when *E*~*max*~ (or *I*~*max*~) was estimated, possibly due to limitations in the observed data. Then, assumptions were made that tumor growth would be completely inhibited and remain stagnant when the maximum effect of DEX is achieved and that its sensitivity to DEX would be maximized when the maximum effect of SUL is reached, which is also seen in other publications \[[@CR25], [@CR26]\].

Although SUL was found to be effective against CSCs by antagonizing D2DR, agonists of D1DR may play a similar role, as both classes of molecules might result in an increase in cellular cyclic adenosine monophosphate (cAMP) levels and decrease in the activity of protein kinase A (PKA) \[[@CR27], [@CR28]\]. In our previous study, dopamine was found to downregulate the CSC frequency by activating D1DR in breast cancer \[[@CR15]\]; PK/PD models were developed for dopamine combined with sunitinib in lung cancer \[[@CR29]\] and combined with axitinib in breast cancer \[[@CR30]\]. An on/off effect model, regardless of PK, was employed to describe the effect of dopamine on the antitumor efficacy of sunitinib or axitinib, as the half-life of dopamine in animals or humans is fairly short \[[@CR31]\]. Moreover, dopamine was found to continuously enhance the effects of sunitinib or axitinib for 3 days after a single dose \[[@CR29], [@CR30]\], while SUL in this study was given every day to maintain the efficacy. The different dosing frequencies might be attributed to the patterns of action of the two agents, because dopamine acts as an agonist activating signaling pathways, but SUL is an antagonist that mainly works by inhibiting D2DR \[[@CR32]\]. Thus, a steady plasma concentration of SUL might be needed to maintain the function. Nevertheless, dopamine can only be administered via intravenous routes \[[@CR33]\], but SUL can be given orally and thus can result in better compliance in clinical application.

Simulations of various dosing schedules were performed and further compared. The dosing frequency of SUL did not show a significant impact on the antitumor efficacy of the combination treatment, but changes in DEX dosing resulted in different outcomes. Basically, a lower dose administered more frequently to achieve the total dose was found to lead to better antitumor efficacy. In addition, the dosing schedule of DEX at 8 mg·kg^−1^·d^−1^ combined with SUL at 50 mg·kg^−1^·d^−1^ administered 6 h after DEX was simulated, and it matched with the external validation data well, which further confirmed the predictive ability of the model. However, the sequential dosing schedule of DEX and SUL seemed to have similar antitumor efficacy with the simultaneous schedule, suggesting the lack of additional benefit.

In summary, a semi-mechanism-based PK/PD model was developed and evaluated based on preclinical data to quantitatively describe the antitumor efficacy of DEX combined with SUL and their synergistic effect in drug-resistant breast cancer. DEX inhibited tumor natural growth, and SUL significantly enhanced the efficacy of DEX. A simulation study demonstrated that a better efficacy could be achieved when DEX was given more frequently, which could be conductive to future studies.
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